I love to translate complex concepts and content into readable prose for any audience and can meet short deadlines. I write on anything but specialize in science, medicine and health, including drug R&D. I also edit scientific and technical articles for publication in multiple forms, including peer-reviewed scientific and clinical journals.
I have a Ph.D in Medicine and Physiology from London University and I have lived in the US since 1989. I have spent 18 years as a pharmaceutical executive and the last 6 in consulting, writing and editing.
-Focus on health, wellness and pharmaceuticals. Specialist in all therapeutic areas, translational medicine, personalized medicine.
-Consulting: Independent business and communications consulting for health related companies: Focus on health communications, patient experience of health and disease, in personalized medicine, translational health sciences, disease management.
-Writing/Communications: Writing/editing/presenting including investor materials, business plans, patient and physician education materials, white papers, reports, grant applications and scientific articles. All therapeutic areas.
- Clients include: Merrimack Pharmaceuticals, Phillip Morris International, GE Healthcare, Open Innovators, Sanofi, Woodrow Wilson Center, Alternative Futures Association.
-Open Innovators, CT. Medical Director (2007-present)
*Knowledge strategy development for diabetic retinopathy, macular degeneration and other retinal diseases. SBIR+NSF grants obtained.
-Pfizer Global Research and Development, New London, CT (1999-2006)
*Senior Director and Head of Science, Communications and Technology for World Wide Drug Safety. Worldwide leadership of Technology Evaluation, Communications, Scientific
*Creator and leader of Pfizer Futures Intelligence Network. Creation of a cross-company network of senior executives with the remit to create evergreen future healthcare scenarios with associated implications for the pharmaceutical industry and for Pfizer, and to incorporate insights into annual strategy setting activities.
-Searle/Monsanto Corporation, St Louis, MO (1994-1999)
*Director of Knowledge Management, Bioinformatics and Communications for Monsanto Corporate
*Liaison between Monsanto and Washington University for $5M annual granting process for translation of basic science to potential therapeutics
*Thrombosis Research Group Leader: Development and implementation of drug discovery platform for anti-thrombotic therapies. 20 direct reports.
-Astra Zeneca (previously ICI Pharmaceuticals), UK (1982-1986).
*Experimental Officer in heart failure and blood pressure research
*SMR International, NY (2008-2009). Teaching executive courses for Knowledge Services
*Mitchell College, New London, CT (2007). Teaching course in clinical trial design
*Washington University School of Medicine, St Louis, MO (1989-1994). Instructor in Cardiovascular Sciences in the Dept Internal Medicine. Teaching experience in surgical techniques and in biological sciences. Participation in NIH SCOR program and acquisition of R01 NIH research grant.
*The Gemma E Moran United Way New London Food Center, CT, Head of vision and strategy development for the New London food system. (2007-present).
*Co-founder and knowledge strategist for New London Food Policy Council (January 2011- present).
-St George’s Hospital Medical School, London University, London, UK 1986-1989. Doctor of Philosophy Degree awarded in Medicine and Physiology. Thesis entitled “Effect of anti-platelet compounds in experimental models of thrombosis and myocardial infarction” (First year completed at Bath University, Bath, UK)
-Nottingham Trent University, Nottingham, UK 1978-1982. B.Sc (with honours) in Applied Biology. Specialist areas; Physiology, Pharmacology, Toxicology, Microbiology, Medical Microbiology
• National Coalition of Independent Scholars
• Professional Member of the American Diabetes Association
• Cambridge Who’s Who
• New York Academy of Sciences
• Society of Competitive Intelligence Professionals
• Institute for Noetic Sciences
• Integral Institute
• American Association for the Advancement of Science
• World Futures Society
• Society of Toxicology
• Board Member, Gemma E Moran United Way Food Center, New London, CT
• Editorial Board, Personalized Medicine, Future Science Group, London
1. Torr-Brown, S. Regulatory and Ethical Challenges of Personalized Medicine. 7(5), 465-468, 2010.
2. Torr-Brown, S. Advances in Knowledge Management for Pharmaceutical Research and Development. Current Opinion in Drug Discovery and Development. 8 (3), 316-322, 2005, May.
3. Torr-Brown SR. Sobel BE. Antiplatelet effects of urokinase and their clinical implications. Coronary Artery Disease. 7(1):63-8, 1996 Jan.
4. Abendschein DR. Meng YY. Torr-Brown S. Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor.
Circulation. 92(4):944-9, 1995 Aug 15.
5. Torr-Brown SR. Sobel BE.Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thrombosis Research. 75(4):473-7, 1994 Aug 15.
6. Torr-Brown SR. Nachowiak D. Fujii S. Sobel BE.Lack of degradation of antithrombin III by tissue-type plasminogen activator or plasmin. Coronary Artery Disease. 5(7):625-31, 1994 Jul.
5. Torr-Brown SR. Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Research. 72(5):413-21, 1993 Dec 1.
8. Prager NA. Torr-Brown SR. Sobel BE. Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Journal of the American College of Cardiology. 22(1):296-301, 1993 Jul.
9. Torr SR. Nachowiak DA. Fujii S. Sobel BE. "Plasminogen steal" and clot lysis.
Journal of the American College of Cardiology. 19(5):1085-90, 1992 Apr.
10. Torr SR. Eisenberg PR. Sobel BE. The dependence of activation of platelets by a plasminogen activator on the evolution of thrombin activity. Thrombosis Research. 64(4):435-44, 1991 Nov 15.
11. Torr SR. Haskel EJ. VonVoigtlander PF. Bergmann SR. Abendschein DR.Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor. Journal of the American College of Cardiology. 18(7):1804-10, 1991 Dec.
12. Haskel EJ. Torr SR. Day KC. Palmier MO. Wun TC. Sobel BE. Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation. 84(2):821-7, 1991 Aug.
13. Torr SR. Winters KJ. Santoro SA. Sobel BE. The nature of interactions between tissue-type plasminogen activator and platelets. Thrombosis Research. 59(2):279-93, 1990 Jul 15.
14. Torr S. Noble MI. Folts JD. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
Cardiovascular Research. 24(6):465-70, 1990 Jun.
15. Torr S. Drake-Holland AJ. Main M. Hynd J. Isted K. Noble MI. Effects on infarct size of reperfusion and pretreatment with beta-blockade and calcium antagonists. Basic Research in Cardiology. 84(6):564-82, 1989 Nov-Dec.
16. Collis MG. Keddie JR. Torr SR. Evidence that the positive inotropic effects of the alkylxanthines are not due to adenosine receptor blockade. British Journal of Pharmacology. 81(2):401-7, 1984 Feb.